Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome

Curr Urol Rep. 2016 Jan;17(1):1. doi: 10.1007/s11934-015-0563-1.

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disease characterized by pelvic pain, usually with urinary frequency. These symptoms make patients suffer from a poor quality of life. However, there is still a lack of consensus on the pathophysiology and curable treatment of IC/BPS. We have reviewed several candidates for the pathophysiology of this disease and also treatments that have been used. Although several oral medications, bladder instillation therapies, fulguration for Hunner's lesion, and hydrodistention have been tried as IC/BPS treatments, their outcomes have not been satisfactory. As the application of stem cell therapy is expanding into the urologic field, innovative strategies have been tested with animal models of IC/BPS and have shown promising therapeutic effects for reversing the symptoms of this disorder. Although several concerns about stem cell sources and their safety should be addressed before initiating human clinical trials, we introduce stem cell therapy as a valuable future treatment approach for IC/BPS.

Keywords: Bladder pain syndrome; Interstitial cystitis; Mesenchymal stem cell.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Intravesical
  • Animals
  • Cell- and Tissue-Based Therapy*
  • Cystitis, Interstitial / physiopathology
  • Cystitis, Interstitial / therapy*
  • Humans
  • Pelvic Pain / physiopathology
  • Pelvic Pain / therapy*
  • Quality of Life
  • Stem Cells*